GSK, J&J and Pfizer vie for $10B RSV vaccine market, with Bavarian Nordic and Moderna hot on their trail
Covid-19 isn’t the only respiratory virus wreaking havoc around the world and pushing a bevy of drugmakers to invest in a vaccine.
Respiratory syncytial virus, or RSV, has also seen an unusual summer resurgence, and although it usually causes mild, cold-like symptoms, according to the CDC, RSV can be deadly, especially for infants and older adults.
In the US, the CDC estimates that more than 177,000 of adults over the age of 65 are hospitalized from RSV, and 14,000 of them die each year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
